Novo Nordisk A/S Q3 2025 Earnings Recap

NOVO-B.CO Q3 2025 November 7, 2025

Novo Nordisk reported robust Q3 2025 results, achieving 15% sales growth and 10% operating profit growth, while narrowing guidance due to anticipated lower growth in GLP-1 diabetes and obesity treatments.

Earnings Per Share Miss

$4.56 vs $4.97 est.

-8.2% surprise

Revenue Miss

74976000000 vs 77617281960 est.

-3.4% surprise

Market Reaction

1-Day +1.2%

5-Day +6.82%

30-Day +2.75%

Key Takeaways

Approved Rybelsus with cardiovascular indications in the U.S. and EU, enhancing portfolio in diabetes care.
Obesity care sales surged 41%, significantly boosted by a 168% increase in Wegovy, underscoring strong demand.
Initiated a company-wide transformation expected to lead to DKK 8 billion in annual savings by 2026, focusing resources on diabetes and obesity.
Operational efficiency improvements are anticipated from the reduction of approximately 9,000 global positions, aiming to enhance shareholder returns.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit NOVO-B.CO on AllInvestView.